Application to start phase I trials with cathepsin K filed with authorities

Huddinge – Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, announced today that it will file an application to a European regulatory agency to begin phase I clinical trials with MIV-711, a cathepsin K inhibitor for the treatment of bone disorders such as osteoporosis, osteoarthritis or bone metastases.

Based on the encouraging results of the preclinical safety and toxicology studies carried out with MIV-711, a decision has been taken to initiate clinical development of MIV-711and an application for clinical trial authorization will be filed. The first clinical study is planned to commence as soon authorization has been granted.

 
For more information about Medivir, please contact:

 
About Medivir
Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is TMC435, a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir’s first product, the unique cold sore product Xerese®/Xerclear®, was launched on the US market in 2011. Xerese®/Xerclear®, which has been approved in both the US and Europe, is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company’s website: www.medivir.com

Tags: